Positron emission tomography with computed tomography (PET-CT) to evaluate the response of bone metastases to non-surgical treatment.
A case of solitary bone metastasis from breast cancer, where MRI assessment of treatment response was inaccurate and whole-body fluorodeoxyglucose ((18)FDG) positron emission tomography with computed tomography (PET-CT) proved more reliable and objective, is presented.
Beatson West of Scotland Cancer Centre, Clinical Oncology, Gartnavel General Hospital, Glasgow, UK.
Peter Denzil
PD
Correa
Raj Kumar
RK
Shrimali
Sai
S
Han
Mohammed
M
Rizwanullah
D047072:Aromatase Inhibitors / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000473:pathology* / Q000601:surgery; D004164:Diphosphonates / Q000627:therapeutic use; D018450:Disease Progression; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D000077557:Ibandronic Acid; D000077289:Letrozole; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D064847:Multimodal Imaging; D009570:Nitriles / Q000627:therapeutic use; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D013125:Spinal Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000556:secondary*; D014057:Tomography, X-Ray Computed; D014230:Triazoles / Q000627:therapeutic use
D047072:Aromatase Inhibitors; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D009570:Nitriles; D019275:Radiopharmaceuticals; D014230:Triazoles; D019788:Fluorodeoxyglucose F18; D000077289:Letrozole; D000077557:Ibandronic Acid